Press Room

RDD Europe 2017

Start
Tuesday, April 25, 2017 - 00:00
End
Friday, April 28, 2017 - 00:00
Location: Nice, France
Booth Number: table 35
drug product manufacturing | Hovione

The Respiratory Drug Delivery Europe 2017 will take place in Nice, France and Hovione will be present with a table (nr. 35), a podium presentation, a workshop and a set of posters.

 

HOVIONE PODIUM PRESENTATION

Supercritical-CO2 assisted Spray Drying: Benchmarking Performance, Stability and Scalability of Composite Particles against Conventional Spray Drying
Speaker: Márcio Temtem
Date: Friday, April 28
Time: 10:30 AM

 

HOVIONE WORKSHOP

Advanced Characterization and Design of Inhalable Powder Formulations
Date: Wednesday, April 26
Time: From 2:00 to 6:00 PM

Introduction: Use of advanced analytical characterization tools at all stages of the development of inhaled formulations, from particle engineering to dosing, promotes optimal product design. Combining simple and efficient inhaler design with particle engineering and formulation development can help to achieve the target product profile.

 

HOVIONE POSTERS

Scale-up of a DPI Carrier-based Formulation and Blending Process Optimization by Multivariate Statistical Analysis of a Design of Experiments
Filipa Maia

On the use of Differential Scanning Fluorimetry to Assess the Impact of Spray Drying on Superoxide Dismutase for Dry Powder Inhaler Formulations
Diana Fernandes

Optimization of Formulation and Process Parameters for the Manufacture of Inhalable Composite Particles by Spray-Drying – Effect of Two API Concentration on the In-vitro Aerodynamic Performance
Maria Palha

Paddle over disk as a dissolution test for orally inhaled fluticasone propionate: impact of temperature, dose and formulation
Beatriz Fernandes

 

 

If you are attending RDD Europe and would like to chat with us about your challenges, schedule a meeting with us. Our colleagues will be pleased to meet you.

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024